J Alzheimers Dis 2025 (Jun 24): 13872877251351329

Figure 1.

Study flow diagram. DPP-4i: dipeptidyl-peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonist; SGLT2i: sodium-glucose cotransporter-2 inhibitor; SU: sulfonylurea; T2D: type 2 diabetes mellitus; TZD: thiazolidinedione. *The combined total of patients (n = 1,646,728) in the comparison arm is not a sum of the patients from each of the 7 comparison antidiabetic medication groups because a patient could be prescribed more than one antidiabetic medication during the study period, though there was no overlap between semaglutide and each of the comparison medication groups.

^†   Other GLP-1RAs included albiglutide (1.2%), dulaglutide (85.1%), exenatide (18.0%),
liraglutide (57.0%), and lixisenatide (2.4%).